Abstract: The invention relates to methods for selective quantification of A-beta or alpha-synuclein aggregates comprising the immobiliZation of anti-A-beta or alpha-synuclein antibodies on a substrate, application of the stool sample to be tested to the substrate, addition of probes labelled for detection which by specific binding to A-beta or alpha-synuclein aggregates mark these and detection of the marked aggregates.

Abstract: Provided is a method for the quantitative and/or qualitative determination of bioindicators, including the following steps: a) immobilizing capture molecules for the bioindicators on a substrate; b) bringing the bioindicators of a sample into contact with the capture molecules; c) immobilizing the bioindicators on the substrate by binding to capture molecules; d) bringing the bioindicators into contact with probes containing at least one detection molecule, and e) removing non-specifically bound molecules and particles; and f) binding the probes to the bioindicators, wherein the probes are capable of emitting a specific detection signal and steps b) and d) can take place simultaneously or d) before b), and wherein probes and capture molecules are used which have affine molecules or molecule parts that bind to at least one specific binding site of the bioindicators and these affine molecules or molecule parts of the probes and capture molecules do not overlap one another.

Abstract: The invention relates to amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease.

Abstract: The present invention relates to a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologs having at least 50% identity and derivatives of RD2 or D3 and also polymers containing or consisting of RD2/D3 homologs having at least 50% identity and derivatives of RD2 and under D3 for use as an analgesic, for use in pain therapy, for use in the treatment of chronic and/or neuropathic pain and/or for inhibiting N-type neuronal calcium channels (NCCs).

Abstract: The invention concerns a method for detecting indicators for determining diseases (disease indicators), in which aggregates of misfolded proteins play a role, and a method for selective quantitation and/or characterization of these disease indicators.

Abstract: The present invention relates to a method for quantitatively and/or qualitatively determining virus particles containing at least one binding site for a capture molecule and at least one binding site for a probe, to a kit for carrying out said method, and to various uses.

Abstract: Amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease.

Abstract: The present invention relates to a polymer comprising at least one monomer, the at least one monomer comprising a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1 or homologs with an identity of at least 80% thereof, and a pharmaceutical composition comprising such a peptide for use in the treatment of amyotrophic lateral sclerosis (ALS).

Abstract: An inorganic nanoparticle is provided (step A) having the size of the aggregate of the protein misfolding disease. Free amino groups or free carboxyl groups are formed (step B) on the surface of the nanoparticle (for functionalizing the nanoparticle surface into an amine- or carboxy-functionalized nanoparticle. Maleinimido spacer carboxylic acid is bound to the free amino groups in step (B). Or, free carboxyl groups in step (B) are converted into NHS esters. Monomers of the protein aggregate are bound i) to the maleinimido spacer carboxylic acids by way of a sulfhydryl group at the free end of the monomers, or ii) to the NHS esters by way of the amino group at the free end of the monomer. A standard is provided for use in the detection of protein aggregates occurring with protein misfolding diseases.

Abstract: The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof.

Abstract: The invention relates to amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease.

Abstract: Provided herein is a method for quantifying protein aggregates of a protein misfolding disease in a sample, comprising: placing a capture molecule A on a substrate; selecting a complex sample comprising an aggregate of the protein misfolding disease; removing insoluble components from the sample; contacting the sample with capture molecule A on a part of the substrate; contacting a calibration standard with the capture molecule A on another part of the substrate, contacting at least one capture molecule B with both the aggregate of the sample and the calibration standard, wherein the capture molecule B can emit a detectable signal; comparing the signals of the at least one capture molecule B arranged on the sample assembly and on the calibration standard, wherein the steps do not have to be carried out successively. A related device, kit, and method for detecting protein aggregates are also provided.

Abstract: The invention relates to the treatment of blood, blood products and organs for the removal and/or detoxification of amyloid-beta oligomers.

Abstract: A method for the quantitative characterization of substances with regard to their properties of binding to amyloid-? (A?) conformers, comprising the steps of: —fractionating a sample including various A? conformers; —immobilizing a biotinylated A? conformer of the desired fraction on the surface of a substrate having high affinity for biotin; and —deriving the binding behavior of an aggregate quality control probe to the desired A? conformer from the measurement signal by determining the kinetic and/or thermodynamic parameters. A device for carrying out the method.

Abstract: The invention relates to a method for detecting aggregates of biotherapeutic substances in a sample, said method involving the following steps: a) applying the sample to be examined to a substrate; b) adding probes which are labeled for the detection and which mark the aggregates of biotherapeutic substances by specifically binding thereto; and c) detecting the labeled aggregates of the biotherapeutic substances wherein step a) can be carried out prior to step b). A kit for carrying out said method is also disclosed.

Abstract: A method for detecting extracellular vesicles in a sample, including the following steps: (a) applying the sample to a substrate, (b) adding probes suitable for detection which mark the extracellular vesicles by specific binding to them; and (c) detecting the extracellular vesicles by measuring a specific signal from the probes; wherein step (b) can be performed prior to step (a).

Abstract: Amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease.

Abstract: The present invention relates to a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologs having at least 50% identity and derivatives of RD2 or D3 and also polymers containing or consisting of RD2/D3 homologs having at least 50% identity and derivatives of RD2 and under D3 for use as an analgesic, for use in pain therapy, for use in the treatment of chronic and/or neuropathic pain and/or for inhibiting N-type neuronal calcium channels (NCCs).

Abstract: A peptide comprising at least one peptide binding to an amyloid beta species, wherein the peptide includes an amino acid sequence that is present in cyclized form. The use of the peptides in medicine, in particular for treating Alzheimer's disease, is disclosed.

Abstract: Peptides specifically binding amyloid beta and to methods of treating and diagnosing Alzheimer's dementia using such peptides are provided.